Literature DB >> 6903557

Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

M R Daha, H M Hazevoet, L A Vanes, A Cats.   

Abstract

Sera from sixteen patients with SLE were investigated for the presence of a factor which would conserve convertase activity on preformed EAClgp 4hu2hu for 30 min at 30 degrees in EDTA. Although such a factor could not be detected readily in the sera, chromatography on DE-52 cellulose yielded fractions appearing as three peaks in one patient and as two peaks in a second patient. These peaks were capable of conserving C42 activity and were designated as F-42. Purification of F-42 from the second peak eluting between 4 and 7 mS on DE-52 was obtained by SP-C50, S-300 and QAE-A50 chromatography. F-42 exhibited charge heterogeneity upon SP-C50 chromatography. On polyacrylamide gel electrophoresis the final material migrated as one band, which coincided with the position of F-42 activity upon eluation from a parallel gel. F-42 had an apparent molecular weight of 150,000 and reacted with anti-IgG in Ouchterlony analysis. Sepharose-bound anti-IgG was capable of neutralizing F-42 activity. The purified material was shown to prolong the half-life (T 1/2) of performed cell-bound C42 in GVB-EDTA at 30 degrees from 5 to 80 min.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6903557      PMCID: PMC1458054     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.

Authors:  M R Daha; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

3.  Serum complement component levels in human glomerulonephritis.

Authors:  E J Lewis; C B Carpenter; P H Schur
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

4.  Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads.

Authors:  P Cuatrecasas
Journal:  J Biol Chem       Date:  1970-06       Impact factor: 5.157

5.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

6.  Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

7.  Heterogeneity, polypeptide chain composition and antigenic reactivity of C3 nephritic factor.

Authors:  M R Daha; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

8.  Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.

Authors:  S Nagasawa; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

9.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

10.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

View more
  18 in total

1.  Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

Review 2.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Modulation of classical C3 convertase of complement by tear lactoferrin.

Authors:  A Kijlstra; S H Jeurissen
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

4.  C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.

Authors:  Y Tanuma; H Ohi; S Watanabe; M Seki; M Hatano
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

Review 6.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

7.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

Authors:  A T Gewurz; S M Imherr; S Strauss; H Gewurz; C Mold
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

Review 10.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.